<description>&lt;p&gt;&lt;strong&gt;This episode of the Dementia Researcher Podcast continues our coverage from the AD PD Conference 2026 in Copenhagen, one of the largest international meetings focused on Alzheimer’s and Parkinson’s disease.&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;Hosted by &lt;a href="https://www.dementiaresearcher.nihr.ac.uk/podcast-profile-professor-louise-serpell/" rel="noopener noreferrer" target="_blank"&gt;Professor Louise Serpell&lt;/a&gt;, the conversation brings together &lt;a href="https://www.dementiaresearcher.nihr.ac.uk/profile-athina-grigoriou-university-of-dundee/" rel="noopener noreferrer" target="_blank"&gt;Athina Grigoriou&lt;/a&gt;, &lt;a href="https://www.dementiaresearcher.nihr.ac.uk/profile-dr-lauren-oneill-university-of-dundee/" rel="noopener noreferrer" target="_blank"&gt;Dr Lauren O’Neill&lt;/a&gt;, and &lt;a href="https://www.dementiaresearcher.nihr.ac.uk/profile-dr-sofie-let-frandsen-vesper-bio/" rel="noopener noreferrer" target="_blank"&gt;Dr Sofie Let Frandsen&lt;/a&gt;, each sharing highlights from across the conference.&lt;/p&gt;&lt;p&gt;The discussion spans a wide range of topics, from the biological role of alpha synuclein and mitochondrial dysfunction, through to emerging therapeutic targets and the growing importance of biomarkers. There is a strong focus on how diseases are more complex and varied than once thought, with increasing attention on stratification, personalised medicine, and early detection.&lt;/p&gt;&lt;p&gt;Alongside the science, the episode also reflects on the importance of patient voices, collaboration across disciplines, and the value of sharing both positive and negative research findings.&lt;/p&gt;&lt;p&gt;This is Part Two of our AD PD 2026 reflections, offering a thoughtful look at where the field is heading next.&lt;/p&gt;&lt;p&gt;ADPD Conference Website - &lt;a href="https://gate.sc/?url=https%3A%2F%2Fadpd.kenes.com%2F&amp;amp;token=25653e-1-1775057258935" rel="noopener noreferrer" target="_blank"&gt;adpd.kenes.com/&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Top Takeaways:&lt;/strong&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Alpha synuclein may have a normal physiological role, not just a pathological one&lt;/li&gt;&lt;li&gt;Mitochondrial dysfunction remains central in Parkinson’s mechanisms&lt;/li&gt;&lt;li&gt;Biomarkers are key for both early detection and patient stratification&lt;/li&gt;&lt;li&gt;Diseases like Parkinson’s and dementia are highly heterogeneous&lt;/li&gt;&lt;li&gt;Personalised medicine is becoming a realistic goal, not just an idea&lt;/li&gt;&lt;li&gt;New therapeutic targets beyond dopamine are emerging&lt;/li&gt;&lt;li&gt;Early stage and presymptomatic intervention is a major focus&lt;/li&gt;&lt;li&gt;Patient and carer perspectives remain underrepresented but essential&lt;/li&gt;&lt;li&gt;Collaboration and openness, including sharing negative results, are vital&lt;/li&gt;&lt;li&gt;More diverse populations are needed to validate biomarkers globally&lt;/li&gt;&lt;/ul&gt;&lt;br/&gt;&lt;p&gt;A transcript of this show, links and show notes and profile on all our guests are available on our website at &lt;a href="https://gate.sc/?url=https%3A%2F%2Fwww.dementiaresearcher.nihr.ac.uk&amp;amp;token=d5c7dc-1-1775057258935" rel="noopener noreferrer" target="_blank"&gt;www.dementiaresearcher.nihr.ac.uk&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Follow us on social media:&lt;/strong&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href="https://gate.sc/?url=https%3A%2F%2Fwww.instagram.com%2Fdementia_researcher%2F&amp;amp;token=92c03e-1-1775057258935" rel="noopener noreferrer" target="_blank"&gt;www.instagram.com/dementia_researcher/&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="https://gate.sc/?url=https%3A%2F%2Fwww.facebook.com%2FDementia.Researcher%2F&amp;amp;token=5fdabc-1-1775057258935" rel="noopener noreferrer" target="_blank"&gt;www.facebook.com/Dementia.Researcher/&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="https://gate.sc/?url=https%3A%2F%2Fwww.twitter.com%2Fdemrescommunity&amp;amp;token=cdff42-1-1775057258935" rel="noopener noreferrer" target="_blank"&gt;www.twitter.com/demrescommunity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="https://gate.sc/?url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fdementia-researcher&amp;amp;token=4905d7-1-1775057258935" rel="noopener noreferrer" target="_blank"&gt;www.linkedin.com/company/dementia-researcher&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="https://gate.sc/?url=https%3A%2F%2Fwww.bsky.app%2Fprofile%2Fdementiare%E2%80%A6archer.bsky.social&amp;amp;token=4e2ca8-1-1775057258935" rel="noopener noreferrer" target="_blank"&gt;www.bsky.app/profile/dementiare…archer.bsky.social&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;br/&gt;&lt;p&gt;&lt;strong&gt;Download and Register with our Community App&lt;/strong&gt;:&lt;/p&gt;&lt;p&gt;&lt;a href="https://gate.sc/?url=https%3A%2F%2Fwww.onelink.to%2Fdementiaresearcher&amp;amp;token=30ce0e-1-1775057258935" rel="noopener noreferrer" target="_blank"&gt;www.onelink.to/dementiaresearcher&lt;/a&gt;&lt;/p&gt;</description>

Dementia Researcher Vodcast

Dementia Researcher

ADPD 2026 Conference Highlights - Part Two

MAR 29, 202647 MIN
Dementia Researcher Vodcast

ADPD 2026 Conference Highlights - Part Two

MAR 29, 202647 MIN

Description

This episode of the Dementia Researcher Podcast continues our coverage from the AD PD Conference 2026 in Copenhagen, one of the largest international meetings focused on Alzheimer’s and Parkinson’s disease.Hosted by Professor Louise Serpell, the conversation brings together Athina Grigoriou, Dr Lauren O’Neill, and Dr Sofie Let Frandsen, each sharing highlights from across the conference.The discussion spans a wide range of topics, from the biological role of alpha synuclein and mitochondrial dysfunction, through to emerging therapeutic targets and the growing importance of biomarkers. There is a strong focus on how diseases are more complex and varied than once thought, with increasing attention on stratification, personalised medicine, and early detection.Alongside the science, the episode also reflects on the importance of patient voices, collaboration across disciplines, and the value of sharing both positive and negative research findings.This is Part Two of our AD PD 2026 reflections, offering a thoughtful look at where the field is heading next.ADPD Conference Website - adpd.kenes.com/Top Takeaways:Alpha synuclein may have a normal physiological role, not just a pathological oneMitochondrial dysfunction remains central in Parkinson’s mechanismsBiomarkers are key for both early detection and patient stratificationDiseases like Parkinson’s and dementia are highly heterogeneousPersonalised medicine is becoming a realistic goal, not just an ideaNew therapeutic targets beyond dopamine are emergingEarly stage and presymptomatic intervention is a major focusPatient and carer perspectives remain underrepresented but essentialCollaboration and openness, including sharing negative results, are vitalMore diverse populations are needed to validate biomarkers globallyA transcript of this show, links and show notes and profile on all our guests are available on our website at www.dementiaresearcher.nihr.ac.ukFollow us on social media:www.instagram.com/dementia_researcher/www.facebook.com/Dementia.Researcher/www.twitter.com/demrescommunitywww.linkedin.com/company/dementia-researcherwww.bsky.app/profile/dementiare…archer.bsky.socialDownload and Register with our Community App:www.onelink.to/dementiaresearcher